Summit Trail Advisors, LLC Kodiak Sciences Inc. Transaction History

Summit Trail Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	SELL	$4.3 - $9.48 $1,836 - $4,047	-427 Reduced 0.48%	89,308 $616,000
Q1 2023 May 04, 2023	BUY	$4.81 - $8.88 $2,053 - $3,791	427 Added 0.48%	89,735 $556,000
Q2 2022 Aug 09, 2022	SELL	$5.04 - $9.48 $90,941 - $171,057	-18,044 Reduced 16.81%	89,308 $682,000
Q1 2022 May 16, 2022	SELL	$7.09 - $89.45 $49 - $626	-7 Reduced 0.01%	107,352 $829,000
Q4 2021 Feb 11, 2022	SELL	$80.85 - $128.49 $22,152 - $35,206	-274 Reduced 0.25%	107,359 $9.1 Million
Q3 2021 Nov 16, 2021	SELL	$81.97 - $106.94 $245 - $320	-3 Reduced -0.0%	107,633 $10.3 Million
Q2 2021 Aug 16, 2021	SELL	$77.2 - $126.54 $7,797 - $12,780	-101 Reduced 0.09%	107,636 $10 Million
Q1 2021 May 17, 2021	SELL	$110.45 - $164.47 $1.38 Million - $2.06 Million	-12,500 Reduced 10.4%	107,737 $12.2 Million
Q3 2020 Nov 16, 2020	BUY	$45.05 - $59.27 $5.42 Million - $7.13 Million	120,237 New	120,237 $14.7 Million
Q3 2020 Nov 16, 2020	SELL	$45.05 - $59.27 $810,900 - $1.07 Million	-18,000 Closed	0 $0
Q2 2019 Aug 08, 2019	BUY	$6.2 - $12.0 $111,600 - $216,000	18,000 New	18,000 $211,000

104

39.8M

7.6K

3.5K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $138M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Summit Trail Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Summit Trail Advisors, LLC with notifications on news.